Background and Aims Minimal change disease (MCD) is the main cause of nephrotic syndrome in pediatric age and it is responsible for 10-25% of the cases in adults. It is characterized by minimal glomerular abnormalities in light microscopy, usually without immunoglobulins or complement deposits in immunofluorescence (IF). There is a subgroup of patients that presents with IgM deposition in IF, which has been described as a more aggressive disease, with frequent relapses [1], dependence of steroids [2] and worse outcomes. Method This is a retrospective study that analyses the follow up of 50 adult MCD patients in the nephrology consult, with diagnosis in childhood or adulthood. They had renal biopsies performed between 2009 and 2022. We did not include inappropriate biopsy samples, biopsies without IF or positive for C1q. We compared the characteristics between IgM positive (IgM+) and IgM negative (IgM-) patients at diagnosis, as well as the number of relapses per year, age of presentation and association with steroid-dependence or steroid-resistance. Results There were 23 (46%) patients in the IgM+ group and 27 (54%) in the IgM- group, with a mean follow-up of 10.2± 7.8 years. The IgM- subgroup was older at biopsy time (52 (30-74) years vs IgM+ 15 (13-23) years; p = 0.001) and this is probably related with the age of disease presentation, which was younger in the IgM+ group (12 (5-16) years vs IgM- 52 (73-13) years; p = 0.001). The groups were similar in sex distribution (IgM+ male n = 15 (55.6%) vs IgM- male n = 10 (44.0%); p = 0.395). There were no differences in diabetes and dyslipidemia frequencies between the two groups (Diabetes: IgM+ n = 1 (4.3%), IgM- n = 3 (11.3%), p = 0.614; Dyslipidemia: IgM+ n = 7 (30.4%), IgM- n = 7 (25.9%), p = 0.723), but the IgM- group had more patients with hypertension (IgM+ n = 2 (8.7%), IgM- n = 9 (33%), p = 0.046). The estimated glomerular filtration rate based on creatinine (eGFRcr) at biopsy time was higher in the IgM+ group (124 (104-130) ml/min/1.73 m2 vs IgM- with 96 (84-111) ml/min/1.73 m2; p = 0.003), but this happens probably due to the age as a confounding variable. In regard to the number of relapses per year, the IgM+ group had significantly more relapses than the IgM- group (IgM+ with 0.61 (0.27-1.00) relapses per year; IgM- with 0.17 (0.01-0.65) relapses per year; p = 0.011). The steroid-dependence (IgM+ n = 15 (65%); IgM- n = 11 (47%); p = 0.084) and the steroid-resistance (IgM+ n = 6 (26%); IgM- n = 3 (11%); p = 0.270) isolated outcomes were not significantly different in the two groups, but when we analyze the composed outcome of steroid-dependence plus steroid-resistance we have worse outcomes in the IgM+ subgroup (IgM+ n = 21 (91.3%); IgM- n = 14 (51.8%); p = 0.04; ORR 9.72; IC 95% 2.37-33.33). An IgM+ patient has 9.7 times the odd of being steroid-dependent or steroid-resistant of an IgM- patient. From our 50 patients, 3 evolved to stage 5 chronic kidney disease with dialysis dependency, being all of those patients IgM+. One of those patients had a recurrency of MCD after kidney transplant. There were 3 deaths with non-related to kidney disease causes, 1 in the IgM+ and 2 in the IgM- groups. Genetic test was performed in 5 of the IgM+ patients, with 4 positive results for mutations. Only 2 IgM- patients did genetic test, all without mutation´s identification. Conclusion This study supports the evidence that MCD patients with IgM+ biopsies have younger age MCD's presentation, more relapses per year and more steroid dependence plus resistance. Dialysis was started in 3 IgM+ patients and this group seems to have higher frequency of genetic mutations. This suggests that genetic testing could be important for future prognosis prediction and treatment options in the IgM+ patients, but further studies with a bigger study population need to be done to establish this relation.
Background and Aims Chronic kidney disease (CKD) prevalence has been increasing and estimates show it will be the fifth leading cause of lost life years worldwide by 2040. CKD patients should be evaluated by Nephrology even in early stages of disease, but patients substantially outnumber nephrologists. Telemedicine consists of delivery of health-care services and information from distant locations and its utility has been largely demonstrated in CKD patients. In our centre, teleconsultation began being used to support requests from family doctors regarding CKD patients that are at that point stable and in an early stage of their disease. Method Since January 2020 and December 2022, 456 patients were evaluated using teleconsultation. Their demographical characteristics and the savings on dislocation cost, based on the price per kilometre, were analysed. In addition, a questionnaire about the use and utility of telenephrology was shared through general practice centres. Results From 456 patients, 43% male and 57% female, with an average age of 78 years. One out of five patients were dependent for daily life activities. On average, the patients lived within 22kms of the hospital, the maximal distance was 540kms. Based on this data we estimate 6660 euros savings on dislocation costs alone. A total of 47 general medicine doctors answered the survey, out of which 21% were male, with an average age of 40 years, 23% had under 5 years of experience, 26% had between 5 and 10 years of experience, 26% between 11 and 15 and the remaining over 16 years of experience. Around 70% had never used the teleconsultation, the majority of which due to lack of knowledge of this possibility. In the group that had used it, 77% were satisfied with the patient's orientation and 85% would consider using it again. Most of the general practitioners (62%) had referenced patients between 2 and 5 times. A fast answer to the request was the most frequently pointed advantage and the time between request and patient orientation was considered appropriate. Conclusion From this data, we conclude that telenephrology is not well known among family doctors in Portugal, yet it has the potential to reduce the distance between patients and nephrologists and build bridges between different areas of specialisation. It will also allow for cost reduction, a matter more pressing each day, and to increase patients comfort by reducing unnecessary hospital visits.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.